European Medical Solutions (STU:AS00) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
European Medical Solutions EBITDA Margin % Related Terms
European Medical Solutions EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AS00 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, European Medical Solutions's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
European Medical Solutions EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, European Medical Solutions's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where European Medical Solutions's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
European Medical Solutions (STU:AS00) has a EBITDA Margin % of 9.59% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on European Medical Solutions and its competitors. This is 76% above median its historical median of 5.45. According to the industry distribution chart, European Medical Solutions ranks #241 out of 945 companies in the Biotechnology industry, placing it in the top 25.5%.
Is European Medical Solutions' EBITDA Margin % too high?
European Medical Solutions' current EBITDA Margin % of 9.59% is 76% above median its 10-year median of 5.45. Based on the distribution chart, European Medical Solutions ranks #241 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, European Medical Solutions has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does European Medical Solutions' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, European Medical Solutions ranks #241 out of 945 companies for EBITDA Margin %. This puts European Medical Solutions in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on European Medical Solutions and its competitors. European Medical Solutions's current EBITDA Margin % is 9.59%, which is 76% above median its own 10-year median of 5.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Medical Solutions stock overvalued right now?
European Medical Solutions (STU:AS00) has a current EBITDA Margin % of 9.59%. The stock's GF Value™ is €8.10, compared to a current price of €4.74 — trading 41.5% below its estimated fair value. The current EBITDA Margin % is 9.59%, which is 76% above median its 10-year median of 5.45. European Medical Solutions' overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For European Medical Solutions (STU:AS00), the current EBITDA Margin % is 9.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is European Medical Solutions (STU:AS00) Overvalued in 2026?
Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued.
The current stock price of €4.74 is trading 41.5% below its estimated GF Value™ of €8.10.
Key valuation signals for STU:AS00:
EBITDA Margin %: 9.59% (76% above median its 10-year median of 5.45)
GF Value™: €8.10 vs. price of €4.74 (41.5% below fair value)
No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
45GF Score
Get the complete analysis for STU:AS00
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AS00 has been successfully added to your 
